ISRCTN00680126已完成未知
A randomised, open-label, multicentre, efficacy and safety study examining the effects on viral kinetics of all-trans retinoic acid (Tretinoin) (VESANOID®) in combination with pegylated interferon alpha-2a (PEGASYS®) and ribavirin (COPEGUS®) therapy in patients with genotype 1-chronic hepatitis C and non-response to a previous course of peg-interferon alpha/ribavirin combination (ATRACTION)
Johannes Gutenberg-University Mainz (Johannes Gutenberg-Universitat Mainz) (Germany)0 个研究点目标入组 57 人开始时间: 2007年10月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 57
研究概览
简要总结
2013 results in https://pubmed.ncbi.nlm.nih.gov/23245590/ (added 10/06/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Serological evidence of chronic Hepatitis C infection by positive anti-HCV testing and detectable HCV-Ribonucleic Acid (RNA) in serum (greater than 100 IE/ml)
- •2. Non-responder to the previous anti-HCV combination therapy with pegylated interferon and ribavirin. Non-response is defined as a lack of at least a greater than two log drop in HCV-RNA at any time point during the previous therapy of at least 12 weeks, or a greater than two log drop at week 12, but HCV-RNA still detectable at week 24. During the previous course pegylated interferon and ribavirin had to be administered in standard dose, that is, for example, at least 1.0 µg/kg/body weight/week pegylated interferon alpha-2b and 800 mg/d ribavirin at the beginning or at least 135 µg/week peginterferon alpha-2a and 800 mg/d ribavirin at the beginning
- •3. Evidence of HCV genotype 1 by means of reverse hybridisation assay Inno LiPA from Bayer Versant (Innogenetics) within 24 months before randomisation
- •4. Histological evidence of inflammation and fibrosis (greater than F1) in the liver with or without evidence of compensated cirrhosis within 24 months before randomisation (Child-Pugh grade A)
- •5. The previous anti-HCV therapy course had to be finished at least 6 months before randomisation into this study
- •6. Men and women aged 18 to 65 years
- •7. Negative urine- or serum-pregnancy test for women with childbearing potential within 24 hours before administration of the first dose of medication (also for fertile female partners of male patients)
- •8. For female patients: during administration of the study medication and during 6 months of treatment free follow-up two highly effective methods of contraception have to be used, one of them with a barrier function, that is condom (accepted methods of contraception are: combined oral contraceptives, implants, injectables, some Intra-Uterine Devices [IUDs], vasectomised partner) (note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals, CPMP/ICH/286/95 mod); micro-dosed gestagenes (Minipill) and oral contraceptives with a content of less than 20 µg ethinylestradiol as a method of contraception are not sufficient when all-trans retinoic acid is used
- •9. For male patients and their female partners: during administration of the study medication and during 7 months of treatment free follow-up two highly effective methods of contraception have to be used, one of them with a barrier function, that is condom (accepted methods of contraception are: combined oral contraceptives, implants, injectables, some IUDs, vasectomised partner) (note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals, CPMP/ICH/286/95 mod); micro-dosed gestagenes (Minipill) and oral contraceptives with a content of less than 20 µg Ethinylestradiol as a method of contraception are not sufficient when all-trans retinoic acid is used
- •10. Written informed consent concerning the participation in the study
- •11. An ophtalmological examination is recommended for all patients before randomisation
排除标准
- •1. Known hypersensitivity to the active substance of pegylated interferon alpha-2a, to alpha-interferons or ribavirin or one of the other ingredients
- •2. Known allergy to a substance of the class of retinoids or one of the other ingredients (e.g. allergy to soy beans or peanuts)
- •3. Persons under age or persons of age, that are not able to realise nature, meaning and significance of the clinical study and to adjust their will in that sense (according to section [§] 40 Abs. 4 and § 41 Abs. 2 and Abs. 3 AMG [Arzneimittelgesetz] - the German law which regulates clinical trials)
- •4. Pregnancy or breastfeeding
- •5. Fertile women, not using highly effective methods of contraception
- •6. Male partners of pregnant women
- •7. Participation in another clinical study at the same time or within the last three months
- •8. Patients already included once into this study
- •9. Persons, that are eventually in dependence on the sponsor or investigator
- •10. Infection with HCV-Genotypes-2, -3, -4, -5 or -6
- •11. Evidence of Hepatitis B surface Antigen (HBsAg), Human Immunodeficiency Virus (HIV)-antibodies during screening
- •12. Patients under immunosuppression
- •13. Treatment with systemic anti-neoplastic or immune modulatory medication (including supraphysiological doses of steroids or radiation) within the last 6 months before randomisation and throughout the whole study duration
- •14. Chronic hepatitis unrelated to Hepatitis-C-virus (e.g. haemochromatosis, autoimmunehepatitis, metabolic- or alcohol-related liver disease)
- •15. Decompensated cirrhosis or liver disease graded Child-Pugh grade B or C
- •16. Signs of a Hepatocellular Carcinoma (HCC) before randomisation in case of a state of cirrhosis or transition to cirrhosis (alpha-fetoprotein values greater than 100 ng/ml lead to exclusion of the patient from the study, with values of alpha-fetoproteins of greater than 50 ng/ml and less than 100 ng/ml an HCC should be excluded by means of an established method)
- •17. Oesophagael varices with bleeding in the medical history
- •18. Haemoglobin less than 12 g/dl for women and less than 13 g/dl for men during screening
- •19. Patients with an elevated risk for anaemia (e.g. thalassemia, spherocytosis, etc.) or patients, for whom anaemia would be a medical risk in particular
- •20. Neutropenia less than 1,500/µl or thrombocytopenia less than 70,000/µl during screening
- •21. Creatinine in serum greater than 1.5 mg/dl during screening
- •22. Acute or known psychic illnesses or disturbances that negatively influence the ability of the patient to understand the requirements of this study
- •23. Severe depression in the medical history, defined as any sign on suicidal tendencies, or hospitalisation because of depression, or any exclusively antidepressive therapy of at least 3 months duration (an accompanying antidepressive treatment in the setting of a previous anti-HCV therapy with Interferons is allowed)
- •24. Severe psychotic or any other severe psychiatric disease in the medical history, defined as any antipsychotic or otherwise psychiatric treatment of at least 3 months duration in the medical history or any sign on suicidal te
研究者
相似试验
已完成
2 期
A randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancerAdvanced oesophago-gastric cancerOesophago-gastric cancerCancerISRCTN65080435The Royal Marsden Hospital NHS Foundation Trust (UK)553
已完成
3 期
A randomised pragmatic open-label, multicentre, non-crossover clinical study to evaluate and compare the efficacy, safety profile and tolerability of oral ibandronate versus intravenous (iv) zoledronate in the treatment of breast cancer patients with bone metastasesCancerISRCTN13914201Velindre NHS Trust1,400
已完成
4 期
Immunotherapy with racotumomab plus best support treatment in comparison to best support treatment alone in advanced non-small cell lung cancer patientsCancerISRCTN47153584Recombio SL (Spain)1,082
已完成
不适用
A prospective, multicentre, randomised trial of carboplatin flat dosing vs. intrapatient dose escalation in first line chemotherapy of ovarian, fallopian tube and primary peritoneal cancersCancerISRCTN47645935niversity of Glasgow (UK)1,300
已完成
3 期
Kids In Control OF Food (KICk-OFF)DiabetesISRCTN37042683Sheffield Children's NHS Foundation Trust (UK)576